Andra AP fonden reduced its stake in shares of Mylan NV (NASDAQ:MYL) by 20.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 151,600 shares of the company’s stock after selling 37,800 shares during the quarter. Andra AP fonden’s holdings in Mylan were worth $2,999,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of Mylan by 19.2% during the second quarter. Vanguard Group Inc. now owns 56,048,375 shares of the company’s stock worth $1,067,160,000 after purchasing an additional 9,026,215 shares during the period. Banco Santander S.A. purchased a new stake in shares of Mylan during the third quarter worth about $55,384,000. Nuveen Asset Management LLC boosted its holdings in shares of Mylan by 824.3% during the second quarter. Nuveen Asset Management LLC now owns 1,681,501 shares of the company’s stock worth $31,898,000 after purchasing an additional 1,499,579 shares during the period. Point72 Asset Management L.P. boosted its holdings in shares of Mylan by 312.6% during the second quarter. Point72 Asset Management L.P. now owns 1,769,543 shares of the company’s stock worth $33,692,000 after purchasing an additional 1,340,643 shares during the period. Finally, AQR Capital Management LLC boosted its holdings in shares of Mylan by 11.0% during the second quarter. AQR Capital Management LLC now owns 11,247,227 shares of the company’s stock worth $213,473,000 after purchasing an additional 1,111,009 shares during the period. 86.54% of the stock is currently owned by hedge funds and other institutional investors.

In related news, insider Goulds Bruce 8,000,000 shares of Mylan stock in a transaction on Friday, November 8th. Company insiders own 0.82% of the company’s stock.

MYL has been the subject of a number of analyst reports. SunTrust Banks increased their target price on shares of Mylan from $25.00 to $27.00 and gave the stock a “buy” rating in a report on Thursday, September 12th. Morgan Stanley lowered shares of Mylan from an “overweight” rating to an “equal” rating and dropped their target price for the stock from $25.00 to $18.00 in a report on Thursday, November 7th. Evercore ISI reiterated a “buy” rating on shares of Mylan in a report on Friday, August 9th. BidaskClub upgraded shares of Mylan from a “sell” rating to a “hold” rating in a report on Thursday, November 28th. Finally, Cfra upgraded shares of Mylan to a “hold” rating in a report on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $27.97.

Shares of MYL opened at $18.66 on Tuesday. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.43 and a quick ratio of 0.84. Mylan NV has a one year low of $16.63 and a one year high of $34.46. The company has a 50-day simple moving average of $18.30 and a two-hundred day simple moving average of $18.88. The firm has a market capitalization of $9.69 billion, a PE ratio of 4.07, a price-to-earnings-growth ratio of 1.01 and a beta of 1.72.

Mylan (NASDAQ:MYL) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $1.17 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.14 by $0.03. Mylan had a net margin of 0.42% and a return on equity of 18.80%. The business had revenue of $2.96 billion during the quarter, compared to analyst estimates of $3.01 billion. During the same period last year, the business posted $1.25 earnings per share. Mylan’s quarterly revenue was up 3.5% compared to the same quarter last year. Analysts expect that Mylan NV will post 4.31 EPS for the current fiscal year.

About Mylan

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.

Further Reading: How do CD ladders protect against rising interest rates?

Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.